Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02995291
Other study ID # 2016-4014
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 10, 2017
Est. completion date September 15, 2019

Study information

Verified date January 2020
Source Dalhousie University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical trials have shown phentolamine mesylate (PM), brand name OraVerse, to be effective at reducing the amount of time to reversal of local anesthesia with different dental anesthetics. However, to date no study investigated the efficacy of phentolamine mesylate to reverse anesthesia induced with the use of Bupivacaine.

The objective of the proposed research is to conduct a pilot-scale randomized clinical trial evaluating the difference in time required for the return of normal soft-tissue sensation and function in participants who have received 0.5% Bupivacaine HCl, 1:200,000 epinephrine, followed by an injection with either 1) OraVerse (phentolamine mesylate) or 2) sterile physiological water (control).


Description:

Dental procedures often require the use of local anesthesia. The most common local anesthetic used is 2% Lidocaine 1:100,000 epinephrine. This local anesthetic can achieve soft tissue anesthesia for 180-300 minutes and pulpal anesthesia for 60 minutes. Unfortunately, for longer treatments this relatively short duration can lead to the loss of anesthetic effect before the end of the interventions. Time-demanding dental appointments include oral and periodontal surgeries, extensive restorative treatments, and even minor treatments when completed by dental students. Unfortunately, if a short acting anesthetic such as Lidocaine is being used during long lasting procedures, once the patients start feeling pain again, it may be difficult to reestablish deep pulpal anesthesia with a repeated injection due to tachyphylaxis. To avoid this situation long-acting local anesthetics could be selected instead. The only long-acting anesthetic available in dentistry is 0.5% Bupivacaine HCl, 1:200,000 epinephrine. Bupivacaine can produce soft tissue anesthesia for up to 12 hours (commonly 4 to 9 hours) and pulpal anesthesia for up to 7 hours (commonly 1.5 to 3 hours). Unfortunately, Bupivacaine is not often used for non-surgical procedures due to its very long soft tissue anesthesia that outlast treatments by several hours.

The effects of soft tissue anesthesia linger for some time after the administration of long acting local anesthetics such as Bupivacaine. This can lead to discomfort and occasionally injury from lip/tongue biting. Clinical trials have shown phentolamine mesylate (PM), brand name OraVerse, to be effective at reducing the amount of time to reversal of local anesthesia with different dental anesthetics. However, to date no study investigated the efficacy of phentolamine mesylate to reverse anesthesia induced with the use of Bupivacaine.

The objective of the proposed research is to conduct a pilot-scale randomized clinical trial evaluating the difference in time required for the return of normal soft-tissue sensation and function in participants who have received 0.5% Bupivacaine HCl, 1:200,000 epinephrine, followed by an injection with either 1) OraVerse (phentolamine mesylate) or 2) sterile physiological water (control). This will further advance our knowledge of both Bupivacaine and phentolamine mesylate as there are no current studies evaluating reversing the effect of Bupivacaine with PM.

It is hypothesized that phentolamine mesylate will reduce the duration of soft tissue anesthesia by 2.5 hours when compared with a control injection of saline water. It is anticipated that this study will determine the feasibility and sample size needed to conduct a full-scale multi-centre trial.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date September 15, 2019
Est. primary completion date May 15, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years of age or older

- capable of providing informed consent

Exclusion Criteria:

- contra-indications for regular dental treatment

- medical history that contraindicates the use of epinephrine

- participant taken an opioid or an opioid like analgesic within 24 hours

- pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
OraVerse
1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
Saline Water (Control)
1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.

Locations

Country Name City State
Canada Dalhousie University Faculty of Dentistry Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
Dalhousie University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to reversal of local anesthesia 8 hours
See also
  Status Clinical Trial Phase
Completed NCT03663478 - Continuous TQL Block for Elective Cesarean Section Phase 4
Completed NCT04513652 - A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution Phase 3
Completed NCT05464862 - The Effect of PPB Using 10, 20 and 30 ml of Lidocaine, Study on Volunteers Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT03245359 - Pain Management After TKA: Comparison of Short- and Long-term Nerve Blocks N/A
Recruiting NCT06028126 - Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial N/A
Not yet recruiting NCT05815563 - Validation of Peripheral Perfusion Index in Predicting Successful Supraclavicular Brachial Plexus Block in Pediatrics
Completed NCT01418690 - Changes in Tissue Oxygenation Following Regional Anesthesia N/A
Suspended NCT03291691 - Protective Nerve Stimulation in Regional Anesthesia
Not yet recruiting NCT03545516 - Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery Phase 2
Not yet recruiting NCT05038007 - Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades Phase 2
Terminated NCT03672500 - Perineal Local Infiltration Study N/A
Enrolling by invitation NCT06057090 - Do Therapy Dogs Improve Behavior and Reduce Anxiety in Pediatric Dental Patients? N/A
Recruiting NCT05415865 - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Phase 3
Recruiting NCT06011005 - Efficacy of Ethyl Chloride Topical Anesthesia Application on the Pain Perception During Intra-oral Injections in Children in Comparison to Benzocaine Gel. N/A
Completed NCT04536311 - Surgical Stabilization of Rib Fractures While Awake or Under Appropriate Sedation by Paravertebral Block N/A
Completed NCT03600454 - The Effect of Anesthesia on Perioperative Muscle Weakness and Neuro-endocrine Stress Response N/A
Recruiting NCT03159338 - Platelet-rich Fibrin on Nerve Regeneration After Bilateral Sagittal Split Osteotomy N/A
Completed NCT02966067 - A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4